AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Food Science and Human Wellness Article
View PDF
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Network pharmacology-based screening of the active ingredients and mechanisms of Cymbaria daurica against diabetes mellitus

Ruyu Shia,b,1, Dongxue Chena,c,1, Mingyue Jib,d, Baochang Zhoua,c, Ziyan Zhanga,c, Chunhong Zhangd,e( ), Minhui Lia,b,c( )
Inner Mongolia Hospital of Traditional Chinese Medicine, Hohhot 010020, China
Inner Mongolia Key Laboratory of Characteristic Geoherbs Resources Protection and Utilization, Baotou Medical College, Baotou 014040, China
Inner Mongolia Institute of Traditional Chinese Medicine, Hohhot 010020, China
Inner Mongolia Engineering Research Center of the Planting and Development of Astragalus membranaceus of the Geoherbs, Baotou Medical College, Baotou 014040, China
Inner Mongolia Key Laboratory of Chinese Medicine Resources, Baotou Medical College, Baotou 014040, China

1 Ruyu Shi and Dongxue Chen contributes equally to this work.

Peer review under responsibility of KeAi Communications Co., Ltd.

Show Author Information

Abstract

Cymbaria daurica L. has a long history as a folk medicine and tea for the treatment of diabetes. However, the biological activity and mechanism of its hypoglycemic effect have not been fully elucidated. In this study, the potential mechanism of C. daurica against type 2 diabetes mellitus (T2DM) was postulated via pharmacological network analysis. Based on data mining techniques involving topological parameters, gene ontology, and pathway enrichment, we established a compound-target, protein-protein interaction, and target-pathway network to identify central targets and pathways. Pathway enrichment analysis revealed that the most important pathway associated with C. daurica in treating T2DM is the PI3K-Akt signaling pathway. Molecular docking was performed to validate the predicted results. Then, a HepG2 cell insulin resistance model and a high-fat, high-glucose diet combined with a streptozotocin-induced T2DM rat model was established to assess the fasting glucose changes and lipid profile after C. daurica treatment, respectively. Finally, real-time PCR and western blotting were used to verify changes in key targets. The anti-diabetic mechanism of the active ingredient in C. daurica may involve the regulation of IRS-2, Akt1, GLUT4, and GSK3β.

Keywords

Molecular dockingInsulin resistanceNetwork pharmacologyDiabetes mellitusCymbaria daurica L.PI3K-Akt signaling pathway

References

[1]

X. Gong, M.Y. Ji, Xu J., et al., Hypoglycemic effects of bioactive ingredients from medicine food homology and medicinal health food species used in China, Crit. Rev. Food Sci. 60 (2020) 2303-2326. https://doi.org/10.1080/10408398.2019.1634517.
DOI Google Scholar
[2]

D.M. Riddy, P. Delerive, R.J. Summers, et al., G protein-coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus, Pharmacol. Rev. 70 (2018) 39-67. https://doi.org/10.1124/pr.117.014373.
DOI Google Scholar
[3]

K. Gao, R. Yang, J. Zhang et al., Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology, Pharmacol. Res. 130 (2018) 93-109. https://doi.org/10.1016/j.phrs.2018.01.011.
DOI Google Scholar
[4]

Q. Ge, L. Chen, M. Tang, et al., Analysis of mulberry leaf components in the treatment of diabetes using network pharmacology, Eur. J. Pharmacol. 833 (2018) 50-62. https://doi.org/10.1016/j.ejphar.2018.05.021.
DOI Google Scholar
[5]

M.G.L.D. Agostino, C.L. Roumie, Sulfonylureas as second line treatment for type 2 diabetes, Can. Fam. Physician 362 (2018) 3041. https://doi.org/10.1136/bmj.k3041.
DOI Google Scholar
[6]

G.M. Pozzuoli, M. Laudato, M. Barone, et al., Errors in insulin treatment management and risk of lipohypertrophy, Acta. Diabetol. 55 (2018) 67-73. https://doi.org/10.1007/s00592-017-1066-y.
DOI Google Scholar
[7]

H. Kashyap, S. Gupta, R. Bist, Impact of active antihyperglycemic components as herbal therapy for preventive health care management of diabetes, Curr. Mol. Med. 19 (2019) 12-19. https://doi.org/10.2174/1566524019666190219124301.
DOI Google Scholar
[8]

X. Zhang, G. Li, D. Wu, et al., Emerging strategies for the activity assay and inhibitor screening of alpha-glucosidase, Food Funct. 11 (2020) 66-82. https://doi.org/10.1039/c9fo01590f.
DOI Google Scholar
[9]

J. Bae, G. Kim, Y.H. Lee, et al., Differential effects of Thiazolidinediones and Dipeptidyl peptidase-4 inhibitors on insulin resistance and β-cell function in type 2 diabetes mellitus: a propensity score-matched analysis, Diabetes Ther. 10 (2019) 149-158. https://doi.org/10.1007/s13300-018-0541-y.
DOI Google Scholar
[10]

S. De, S. Banerjee, S.K.A. Kumar, et al., Critical role of dipeptidyl peptidase Ⅳ: a therapeutic target for diabetes and cancer, Mini Rev. Med Chem. 19 (2019) 88-97. https://doi.org/10.2174/1389557518666180423112154.
DOI Google Scholar
[11]

A.D. Raval, A. Vyas, National trends in diabetes medication use in the United States: 2008 to 2015, J. Pharm. Pract. 33 (2020) 433-442. https://doi.org/10.2174/10.1177/0897190018815048.
DOI Google Scholar
[12]

H.L. Stuckey, U. Desai, S.B. King, et al., The experience of a severe hypoglycemic event from the perspective of people with diabetes and their caregivers: "What am I going to do?", Diabet. Med. (2021) e14745. https://doi.org/10.1111/dme.14745.
DOI Google Scholar
[13]

Y. Ni, L. Ni, F. Zhuge, et al., Adipose tissue macrophage phenotypes and characteristics: the key to insulin resistance in obesity and metabolic disorders, Obesity (Silver Spring) 28 (2020) 225-234. https://doi.org/10.1002/oby.22674.
DOI Google Scholar
[14]

N. Kallscheuer, T. Classen, T. Drepper, et al., Production of plant metabolites with applications in the food industry using engineered microorganisms, Curr. Opin. Biotechnol. 56 (2019) 7-17. https://doi.org/10.1016/j.copbio.2018.07.008.
DOI Google Scholar
[15]

G. Xue, J. Wang, M.Y. Zhang, et al., Bioactivity, compounds isolated, chemical qualitative, and quantitative analysis of Cymbaria daurica extracts. Front Pharmacol, 11 (2020) 48. https://doi.org/10.3389/fphar.2020.00048.
DOI Google Scholar
[16]

C.H. Zhang, D. Man, G.D. Wu, Protection, exploitation and utilization states of specialized Mongolian folk medicine resources and related development strategy, China Journal of Chinese Materia Medica 40 (2015) 771-777.
Google Scholar
[17]

Z.P. Hu, M.Y. Yang, L.J. Yang, et al., Network pharmacology-based identification of the mechanisms of Shen-Qi compound formula in treating diabetes mellitus, Evid. Based Complement Alternat. Med. 4 (2020) 5798764. https://doi.org/10.1155/2020/5798764.
DOI Google Scholar
[18]

Q.Y. Xiao, T.Y. Ye, X.L. Wang, et al., A network pharmacology-based study on key pharmacological pathways and targets of Qi Fu Yin acting on Alzheimer's disease, Exp. Gerontol. 149 (2021) 111336. https://doi.org/10.1016/j.exger.2021.111336.
DOI Google Scholar
[19]

Z. Yang, W. Huang, J. Zhang, et al., Baicalein improves glucose metabolism in insulin resistant HepG2 cells, Eur. J. Pharmacol. 854 (2019) 187-193. https://doi.org/10.1016/j.ejphar.2019.04.005.
DOI Google Scholar
[20]

S.H. Lee, K.H. Yoon, A century of progress in diabetes care with insulin: a history of innovations and foundation for the future, Diabetes Metab. J. 45 (2021) 629-640. https://doi.org/10.4093/dmj.2021.0163.
DOI Google Scholar
[21]

F. Hu, X. Qiu, S. Bu, Pancreatic islet dysfunction in type 2 diabetes mellitus, Arch. Physiol. Biochem. 126 (2020) 235-241. https://doi.org/10.1080/13813455.2018.1510967.
DOI Google Scholar
[22]

Y. Imai, R.S. Cousins, S. Liu, Connecting pancreatic islet lipid metabolism with insulin secretion and the development of type 2 diabetes, Ann. N.Y. Acad. Sci. 1461 (2020) 53-72. https://doi.org/10.1111/nyas.14037.
DOI Google Scholar
[23]

S.L. McMillin, D.L. Schmidt, B.B. Kahn et al., GLUT4 is not necessary for overload-induced glucose uptake or hypertrophic growth in mouse skeletal muscle, Diabetes 66 (2017) 1491-1500. https://doi.org/10.2337/db16-1075.
DOI Google Scholar
[24]

D.M. Norris, T.A. Geddes, D.E. James, et al., Glucose transport: methods for interrogating GLUT4 trafficking in adipocytes, Methods Mol. Biol. 1713 (2018) 193-215. https://doi.org/10.1007/978-1-4939-7507-5_15.
DOI Google Scholar
[25]

N.K. Senftleber, M. Overvad, I.K. Dahl-Petersen, et al., Diet and physical activity in Greenland: genetic interactions and associations with obesity and diabetes, Appl. Physiol. Nutr. Metab. 46 (2021) 849-855. https://doi.org/10.1139/apnm-2021-0020.
DOI Google Scholar
[26]

S.C. Yang, C.Y. Hsu, W.L. Chou, et al., Bioactive agent discovery from the natural compounds for the treatment of type 2 diabetes rat model, Molecules 25 (2020) 5713. https://doi.org/10.3390/molecules25235713.
DOI Google Scholar
[27]

F. Hajiaghaalipour, M. Khalilpourfarshbafi, A. Arya, Modulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitus, Int. J. Biol. Sci. 15 (2015) 508-524. https://doi.org/10.7150/ijbs.11241.
DOI Google Scholar
[28]

P. Mokashi, A. Khanna, N. Pandita, Flavonoids from Enicostema littorale blume enhances glucose uptake of cells in insulin resistant human liver cancer (HepG2) cell line via IRS-1/PI3K/Akt pathway, Biomed. Pharmacother. 90 (2017) 268-277.
DOI Google Scholar
[29]

T. Hussain, B. Tan, G. Murtaza, et al., Flavonoids and type 2 diabetes: evidence of efficacy in clinical and animal studies and delivery strategies to enhance their therapeutic efficacy, Pharmacol. Res. 152 (2020) 104629. https://doi.org/10.1016/j.phrs.2020.104629.
DOI Google Scholar
[30]

B. Dinda, M. Dinda, A. Roy, et al., Dietary plant flavonoids in prevention of obesity and diabetes, Adv. Protein Chem. Struct. Biol. 120 (2020) 159-235. https://doi.org/10.1016/bs.apcsb.2019.08.006.
DOI Google Scholar
[31]

M. Minic, N. Rocha, J. Harris, et al., Constitutive activation of AKT2 in humans leads to hypoglycemia without fatty liver or metabolic dyslipidemia, J. Clin. Endocrinol. Metab. 102 (2017) 2914-2921. https://doi.org/10.1210/jc.2017-00768.
DOI Google Scholar
[32]

X.J. Huang, G.H. Li, J. Guo, et al., The PI3K/AKT pathway in obesity and type 2 diabetes. Int. J. Biol. Sci. 14 (2018) 1483-1496. https://doi.org/10.7150/ijbs.27173.
DOI Google Scholar
[33]

S.Y. Cai, W. Sun, Y.X. Fan, et al., Effect of mulberry leaf (Folium Mori) on insulin resistance via IRS-1/PI3K/Glut-4 signalling pathway in type 2 diabetes mellitus rats, Pharm. Biol. 54 (2016) 2685-2691. https://doi.org/10.1080/13880209.2016.1178779.
DOI Google Scholar
[34]

M.M. Ozmen, C.E. Guldogan, E. Gundogdu, Changes in HOMA-IR index levels after bariatric surgery: comparison of single anastomosis duodenal switch-proximal approach (SADS-p) and one anastomosis gastric bypass-mini gastric bypass (OAGB-MGB), Int. J. Surg. 78 (2020) 36-41. https://doi.org/10.1016/j.ijsu.2020.04.008.
DOI Google Scholar
[35]

M.E. Chen, R.S. Aguirre, T.S. Hannon, Methods for measuring risk for type 2 diabetes in youth: the oral glucose tolerance test (OGTT), Curr. Diab. Rep. 18 (2018) 51. https://doi.org/10.1007/s11892-018-1023-3.
DOI Google Scholar
[36]

Q.W. Guo, Z.Q. Chen, R.K. Santhanam, et al., Hypoglycemic effects of polysaccharides from corn silk (Maydis stigma) and their beneficial roles via regulating the PI3K/Akt signaling pathway in L6 skeletal muscle myotubes, Int. J. Biol. Macromol. 121 (2019) 981-988. https://doi.org/10.1016/j.ijbiomac.2018.10.100.
DOI Google Scholar
[37]

S.Q. Li, H.X. Chen, J. Wang, et al., Involvement of the PI3K/Akt signal pathway in the hypoglycemic effects of tea polysaccharides on diabetic mice, Int. J. Biol. Macromol. 81 (2015) 967-974. https://doi.org/10.1016/j.ijbiomac.2015.09.037.
DOI Google Scholar
[38]

X. Xiao, Q.C. Sun, Y. Kim, et al., Exposure to permethrin promotes high fat diet-induced weight gain and insulin resistance in male C57BL/6J mice, Food Chem. Toxicol. 111 (2018) 405-416. https://doi.org/10.1016/j.fct.2017.11.047.
DOI Google Scholar
[39]

Z.H. Liu, L.T. Xu, M.M. Xing, et al., Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes, Biomed. Pharmacother 125 (2020) 125. https://doi.org/10.1016/j.biopha.2020.109952.
DOI Google Scholar
[40]

L. Goedeke, R.J. Perry, G.I. Shulman, Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes, Annu. Rev. Pharmacol. Toxicol 59 (2019) 65-87. https://doi.org/10.1146/annurev-pharmtox-010716-104727.
DOI Google Scholar
Food Science and Human Wellness
Volume 12 Issue 6,
November 2023
Pages 2001-2013
DOI: 10.1016/j.fshw.2023.03.022
Cite this article:
Shi R, Chen D, Ji M, et al. Network pharmacology-based screening of the active ingredients and mechanisms of Cymbaria daurica against diabetes mellitus. Food Science and Human Wellness, 2023, 12(6): 2001-2013. https://doi.org/10.1016/j.fshw.2023.03.022

516

Views

109

Downloads

3

Crossref

2

Web of Science

2

Scopus

0

CSCD

Altmetrics
Received: 15 August 2021
Revised: 01 September 2021
Accepted: 29 December 2021
Published: 04 April 2023
© 2023 Beijing Academy of Food Sciences.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return